The pharmaceutical industry is New Jersey’s perennial list topper when it comes to measuring what drives the state’s economy, but logistics is never far behind. And, just as often in the Garden State, the two go hand-in-hand. Besides the state’s higher-than-average concentration of drug-dedicated third-party logistics providers, there are a number of little-known players generating big business at the intersection between the pharmaceutical and logistics sectors. It’s par...
READ MORE
|
Shares of Teva Pharmaceutical Industries (NYSE: TEVA), an Israeli-based developer of branded and generic drugs, sank a mind-numbing 45% in 2016, according to data from S&P Global Market Intelligence. The reason for the drop can primarily be traced to four factors....
HOST.MADISON.COM
READ MORE
|
Up to 10 years of safety data has paid off for Merck KGaA’s oral multiple sclerosis treatment Mavenclad. The drug has returned from the dead, eight years after an FDA rejection dashed its dream of challenging Novartis’ then-newly-minted Gilenya—and according to one analyst, it might just be a blockbuster. Maveclad (cladribine) is now approved to treat relapsing forms of MS, including relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS), the FDA sai...
FIERCEPHARMA
READ MORE
|
ViiV Healthcare’s Juluca has been green-lighted in the US as the first two-drug regimen for some patients with HIV. Juluca is comprised of ViiV’s dolutegravir, an integrase strand transfer inhibitor, and Janssen’s rilpivirine 25mg, a non-nucleoside reverse transcriptase inhibitor....
READ MORE
|
NICE has published new standards set out the requirements needed to develop digital health technologies for the NHS and speed up the uptake of products like healthcare apps and wearable devices. Working collaboratively NHS England, NICE, NHS Digital, MedCity, Public Health England, and DigitalHealth. London has been engaging with industry, commissioners, and innovators to understand what is required for health technology to thrive in the UK. The resulting standards have been developed to support...
READ MORE
|
Purdue Pharma is seeking to dismiss a Massachusetts lawsuit filed by that state’s attorney general that has been highly critical of the company’s marketing of its opioid pain treatment OxyContin and has also placed blame on the company for 670 opioid-related deaths in the state since 2009. On Friday, Connecticut-based Purdue filed a motion to dismiss the state’s complaint, which also pointed to how important the success of OxyContin was to the company’s bottom line. The m...
READ MORE
|